AGIOS PHARMACEUTICALS, INC. 8-K

What Happened

• Agios Pharmaceuticals, Inc. filed an 8-K on June 18, 2026 reporting results of its 2026 Annual Meeting. The most important outcome: stockholders approved an amendment to the Agios 2023 Stock Incentive Plan that increases the pool by 2,000,000 shares of common stock and increases the number of shares eligible for incentive stock options by 2,000,000. The amended plan (the “2023 Plan Amendment”) was previously adopted by the Board subject to stockholder approval.
• At the same meeting, stockholders elected three Class I directors (Rahul Ballal, Ph.D.; Brian Goff; Cynthia Smith) for three-year terms, approved the non‑binding advisory vote on executive compensation (“say-on-pay”), and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the current fiscal year.

Key Details

• 2023 Plan Amendment: increases shares available under the 2023 Stock Incentive Plan by 2,000,000 shares; increases incentive stock option limit by 2,000,000 shares.
• Director election votes:
  • Rahul Ballal: For 40,145,081; Withheld 5,943,999; Broker non-votes 2,554,446.
  • Brian Goff: For 45,757,238; Withheld 331,843; Broker non-votes 2,554,446.
  • Cynthia Smith: For 31,496,376; Withheld 14,592,704; Broker non-votes 2,554,446.
• Say-on-Pay: For 43,396,045; Against 1,086,059; Abstain 1,606,976; Broker non-votes 2,554,446.
• Auditor ratification (PwC): For 48,511,213; Against 116,938; Abstain 15,376.

Why It Matters

• The 2,000,000-share increase to the equity award pool can enable the company to grant more stock-based compensation to employees and executives; this can support hiring and retention but may increase potential share dilution for existing shareholders.
• Director elections and the advisory say-on-pay vote provide governance signals—management’s compensation approach received majority support, and PwC’s ratification maintains continuity in external audit oversight.
• These are governance-level actions (not financial results). Investors should monitor future disclosures for any new equity grants or programs that would use the expanded plan and for any potential dilution impact.